AP
- Pfizer is betting big on cancer treatments.
- On Monday, the company said that it was acquiring Seagen in a $43 billion deal.
- Seagen sells four cancer drugs and is expected to bring in $2.2 billion in revenue this year.
Pfizer is betting big on cancer treatments.
The pharmaceutical giant announced on Monday that it would acquire cancer drug developer Seagen, which specializes in a new kind of drug technology that can home in on tumors.